GALDERMA LABS LP
NDA · approvedNDA211527
Approved2019Studies4,253Trials343
Skin & Topicals — 9 products on the FDA record
10 of 136 products · 9 NDA · 1 No matched record
510(k) clearances per year
2015–2026 · 2026 partial
| Skin & Topicals | Total | |
|---|---|---|
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 0 | 0 |
510(k) clearance decisions per year in this category's device codes — filing activity, not sales or clinical benefit. What this measuresCount of FDA 510(k) clearance decisions per year whose product code is in each Dalphene category group. Not approvals, not efficacy, not safety, not sales — filing activity only. Category groups include broad-mixed codes (GEX in lasers-light, GEI in rf-microneedling, NGX in body-contouring), so these yearly totals carry non-aesthetic devices too; the per-code split is not fetched per year. 2026 is a partial year through the run date. Unlike the monthly series, these are count queries — there is no narrow-only variant here because a per-breadth split would double the request count. Charts using this series must carry the broad-mixed caveat on the chart. 2026 covers 01-01 through the run date (2026-07-26) only.
Methodology →
10 products
GALDERMA LABS LP
NDA · approvedNDA020380
Approved1996Studies4,253Trials343
Maker —
Unverified mapping
Decision—Studies166Trials9
ABBVIE
NDA · approvedNDA022369
Approved2008Studies128Trials28
VALEANT PHARMS NORTH
NDA · approvedNDA021108
Approved2000Studies4,253Trials343
BAUSCH
NDA · approvedNDA017340
Approved1973Studies4,253Trials343
KENVUE BRANDS
NDA · approvedNDA019501
Approved1988Studies—Trials—
ALMIRALL
NDA · approvedNDA020600
Approved1997Studies4,253Trials343
GALDERMA LABS LP
NDA · approvedNDA021112
Approved2002Studies1,116Trials51
SUN PHARM
NDA · approvedNDA213433
Approved2020Studies90Trials21
| Product | Manufacturer | Category | Pathway | Class | First decision | Studies | Trials |
|---|---|---|---|---|---|---|---|
| Aklief | GALDERMA LABS LP | Skin & Topicals | NDA — approved | — | Oct 4 2019 | 4,253 | 343 |
| Differin | GALDERMA LABS LP | Skin & Topicals | NDA — approved | — | May 31 1996 | 4,253 | 343 |
| HydraFacial | — | Skin & Topicals | Not verified | — | — | 166 | 9 |
| Latisse | ABBVIE | Skin & Topicals | NDA — approved | — | Dec 24 2008 | 128 | 28 |
| Renova | VALEANT PHARMS NORTH | Skin & Topicals | NDA — approved | — | Aug 31 2000 | 4,253 | 343 |
| Retin-A | BAUSCH | Skin & Topicals | NDA — approved | — | Jan 26 1973 | 4,253 | 343 |
| Rogaine | KENVUE BRANDS | Skin & Topicals | NDA — approved | — | Aug 17 1988 | — | — |
| Tazorac | ALMIRALL | Skin & Topicals | NDA — approved | — | Jun 13 1997 | 4,253 | 343 |
| Tri-Luma | GALDERMA LABS LP | Skin & Topicals | NDA — approved | — | Jan 18 2002 | 1,116 | 51 |
| Winlevi | SUN PHARM | Skin & Topicals | NDA — approved | — | Aug 26 2020 | 90 | 21 |
No product matches these filters.
Missing a device? Report it and it goes into the monthly review.
Curated seed list; study and trial counts are per modality, not per brand. What this measuresThis is a curated seed list of widely used medical-aesthetic products, each crosswalked to a real FDA record where one could be found with confidence. Being listed is not an endorsement, not a ranking and not a claim of market share. Being absent is not a judgement — it means the product is not in this seed list yet. Counts beside each filter are live counts of the products currently matching your other filters. Manufacturer is the applicant or sponsor field of the FDA record, printed exactly as FDA publishes it, so one company can appear under more than one string.
Methodology →
Sorted by most recent FDA decision — a filing date, not a quality signal. What each ordering measuresEvery ordering on this page is a proxy built from public records, never a quality judgement. Orders products by the most recent FDA decision date matched to the brand name, including later submissions and supplements. A recent date means the manufacturer filed again; it does not mean the product is newer, improved, more popular or better. Orders products by the number of PubMed records matching a fixed query for the product's MODALITY, never its brand name. It counts how much has been published about a technique. It is not a quality score, not an efficacy measure, not a count of randomised trials, and not comparable between techniques of different ages. Orders products by the number of ClinicalTrials.gov studies matching a fixed intervention-plus-condition query for the product's MODALITY, never its brand. Registration is not completion, not publication and not a result. Alphabetical by product name. No ranking, quality judgement or ordering of merit is implied by the position of anything in this list. Orders products by the earliest FDA decision date matched to the brand name. For drugs approved under a BLA or NDA the original approval can long predate any cosmetic indication, so an early date is not a cosmetic-use date.
Methodology →